Cellectis S.A.

Phase 1 AI-extracted

eti-cel

relapsed or refractory non-Hodgkin lymphoma (r/r NHL)

Countdown

87days

Phase 1 readout · ~ Oct 1, 2026 estimated

What's at stake Phase 1 trial results for eti-cel in relapsed or refractory non-Hodgkin lymphoma (r/r NHL) are due ~ Oct 1, 2026. A clean hit validates the program; a miss can gap the stock down hard.

Primary source · SEC 6-K verified 10h ago

“Cellectis expects to present the full Phase 1 dataset in 2026, including results from the IL-2 combination.”

Add to calendar Post on X Reddit

Provenance